Publications by authors named "Ingeborg M M van Leeuwen"

Claim this Profile
C
Correction: Modulation of p53 C-Terminal Acetylation by Mdm2, p14ARF, and Cytoplasmic SirT2.
Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, Anna R McCarthy, Marijke C C Sachweh

Mol Cancer Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Marcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, Su Chu, Alan R Healy

Nat Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.
Marcus J G W Ladds, Gergana Popova, Andrés Pastor-Fernández, Srinivasaraghavan Kannan, Ingeborg M M van Leeuwen

J Biol Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
Marcus J G W Ladds, Andrés Pastor-Fernández, Gergana Popova, Ingeborg M M van Leeuwen, Kai Er Eng

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Marcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, Su Chu, Alan R Healy

Nat Commun· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase.
Joana Costeira-Paulo, Joseph Gault, Gergana Popova, Marcus J G W Ladds, Ingeborg M M van Leeuwen

Cell Chem Biol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Marcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, Su Chu, Alan R Healy

Nat Commun· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.
Anna R McCarthy, Marijke C C Sachweh, Maureen Higgins, Johanna Campbell, Catherine J Drummond, Ingeborg M M van Leeuwen

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.
Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, Anna R McCarthy, Marijke C C Sachweh

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclotherapy: opening a therapeutic window in cancer treatment.
Ingeborg M M van Leeuwen

Oncotarget· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.
Ingeborg M M van Leeuwen, Bhavya Rao, Marijke C C Sachweh, Sonia Laín

Cell Cycle· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism-specific signatures for small-molecule p53 activators.
Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, Christopher J Brown, Anna R McCarthy

Cell Cycle· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs.
Ingeborg M M van Leeuwen, Sonia Laín

Oncotarget· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic energy budget approaches for modelling organismal ageing.
Ingeborg M M van Leeuwen, Julio Vera, Olaf Wolkenhauer

Philos Trans R Soc Lond B Biol Sci· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
Bhavya Rao, Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, Alastair M Thompson

Oncotarget· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the interactions between the adhesive and transcriptional functions of beta-catenin in normal and cancerous cells.
Ingeborg M M van Leeuwen, Helen M Byrne, Oliver E Jensen, John R King

J Theor Biol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards a multiscale model of colorectal cancer.
Ingeborg M M van Leeuwen, Carina M Edwards, Mohammad Ilyas, Helen M Byrne

World J Gastroenterol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling microbial adaptation to changing availability of substrates.
Bernd W Brandt, Fleur D L Kelpin, Ingeborg M M van Leeuwen, Sebastiaan A L M Kooijman

Water Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compounds.
Bernd W Brandt, Ingeborg M M van Leeuwen, Sebastiaan A L M Kooijman

Water Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis